Back to results
US 8,148,076 B2Granted
Gene expression profiling of EGFR positive cancer
AssigneeGenomic Health, Inc.
InventorsJoffre B. Baker, Maureen T. Cronin, Steven Shak, Jose Baselga
Life of this patent
Estimating the term…
Abstract
The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
Claims8
A method for predicting the likelihood that a human colon cancer patient will exhibit a clinically beneficial patient response to treatment with cetuximab, the method comprising:
- a) assaying a normalized level of an RNA transcript in a sample comprising EGFR-expressing colon cancer cells obtained from said patient, wherein the RNA transcript is the transcript of EREG;
- b) analyzing the normalized level of the EREG RNA transcript;
- and
- c) predicting the likelihood of response of the patient to treatment with cetuximab by comparing the normalized level of the EREG RNA transcript to gene expression data obtained from reference samples derived from patients with colon cancer, wherein an increased normalized level of the EREG RNA transcript correlates with an increased likelihood of response to treatment with cetuximab.
1 more element
Dependencies are inferred from the claim text.